Loading
A phase 2 trial of Prexasertib run by H. Lee Moffitt Cancer Center and Research Institute, now recruiting.
A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC is a phase 2 interventional study registered as NCT06597565 by H. Lee Moffitt Cancer Center and Research Institute, with 43 participants planned, started 2024-09-25. Conditions recorded: Head and Neck Squamous Cell Carcinoma. Interventions recorded: Gemcitabine and ACR-368.
Shares Prexasertib, Acrivon Therapeutics and the tag pipeline.
Shares Acrivon Therapeutics and the tag pipeline.
Shares Acrivon Therapeutics and the tag pipeline.
Shares Acrivon Therapeutics and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/